ANDA 90547, held by Mylan Pharmaceuticals. Voriconazole.
As of Nov 21, 2026, ANDA 90547 (Voriconazole), held by Mylan Pharmaceuticals, was first approved by FDA on Apr 22, 2010, with 15 approved supplements and 0 published complete response letters.
Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis Candidemia in non-neutropenics and other deep tissue Candida infections Esophageal candidiasis Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy 1.1 Invasive Aspergillosis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2010 | Original application | Approved |
| Voriconazole50MG · tablet;oral | Voriconazole | Rx |
| Voriconazole200MG · tablet;oral | Voriconazole | Rx |
| Nov 16, 2026 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 23, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 11, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 12, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 12, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 27, 2013 | Supplement 2Labeling | Approved | None posted |
| Mar 9, 2011 | Supplement 1Labeling | Approved | None posted |
| Apr 22, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters